These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12170277)

  • 1. Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.
    Asmus MJ; Hendeles L; Weinberger M; Ahrens RC; Bisgaard H; Lötvall J; O'Byrne PM; Cockcroft DW
    J Allergy Clin Immunol; 2002 Aug; 110(2):325; author reply 325-8. PubMed ID: 12170277
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma.
    Chowdhury BA
    J Allergy Clin Immunol; 2002 Aug; 110(2):324; author reply 325-8. PubMed ID: 12170276
    [No Abstract]   [Full Text] [Related]  

  • 3. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?
    Asmus MJ; Hendeles L
    Pharmacotherapy; 2000 Feb; 20(2):123-9. PubMed ID: 10678290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.
    Tripp K; McVicar WK; Nair P; Corren J; Pleskow WW; Goodwin E; Baumgartner RA; Hanrahan JP
    J Allergy Clin Immunol; 2008 Sep; 122(3):544-9. PubMed ID: 18692886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.
    Milgrom H; Skoner DP; Bensch G; Kim KT; Claus R; Baumgartner RA;
    J Allergy Clin Immunol; 2001 Dec; 108(6):938-45. PubMed ID: 11742271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma.
    Hamilos DL; D'Urzo A; Levy RJ; Marcus M; Tripp K; Parsey M; Baumgartner RA; McVicar WK
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):540-8. PubMed ID: 18219836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.
    Nelson HS; Bensch G; Pleskow WW; DiSantostefano R; DeGraw S; Reasner DS; Rollins TE; Rubin PD
    J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):943-52. PubMed ID: 9847435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
    Gawchik SM; Saccar CL; Noonan M; Reasner DS; DeGraw SS
    J Allergy Clin Immunol; 1999 Apr; 103(4):615-21. PubMed ID: 10200010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levalbuterol versus albuterol.
    Ameredes BT; Calhoun WJ
    Curr Allergy Asthma Rep; 2009 Sep; 9(5):401-9. PubMed ID: 19671384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta2-agonist eutomers: a rational option for the treatment of asthma?
    Boulton DW; Fawcett JP
    Am J Respir Med; 2002; 1(5):305-11. PubMed ID: 14720033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
    Truitt T; Witko J; Halpern M
    Chest; 2003 Jan; 123(1):128-35. PubMed ID: 12527613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
    FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise-induced asthma.
    Stempel DA
    N Engl J Med; 1998 Dec; 339(24):1784; author reply 1785. PubMed ID: 9867556
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhaled corticosteroid therapy in asthma: a balancing act.
    Li JT
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):229-30. PubMed ID: 10094213
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience with levalbuterol.
    Nelson HS
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S77-84. PubMed ID: 10452792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting beta 2-agonists and their role in asthma management.
    Galant SP
    West J Med; 1995 Oct; 163(4):372. PubMed ID: 7483600
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of Long-Acting Beta-Agonists in Children with Asthma.
    Bush A; Frey U
    N Engl J Med; 2016 Sep; 375(9):889-91. PubMed ID: 27579641
    [No Abstract]   [Full Text] [Related]  

  • 18. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
    Berger WE
    Ann Allergy Asthma Immunol; 2003 Jun; 90(6):583-91; quiz 591-2, 659. PubMed ID: 12839314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con].
    Ameredes BT; Calhoun WJ
    Am J Respir Crit Care Med; 2006 Nov; 174(9):965-9; discussion 972-4. PubMed ID: 17060667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.